Unravel Biosciences, Inc.


Unravel Biosciences is dedicated to transforming drug development for complex disorders by clinically derisking new targets using existing drugs. Their mission is to accelerate the discovery of effective treatments, ensuring all patients have access to safe and effective therapies. They leverage deep science, AI-powered patient data, and innovative platforms like BioNAV and rareSHIFT to rapidly identify therapeutic mechanisms and develop new therapies. Their work includes clinical trials, collaborations, and a focus on rare diseases such as Rett syndrome and Pitt Hopkins syndrome.

Industries

biotechnology
health-care
medical

Nr. of Employees

small (1-50)

Unravel Biosciences, Inc.

Boston, Massachusetts, United States, North America


Products

Repurposed histone deacetylase inhibitor formulation (clinical-stage) for neurodevelopmental disorders

A reformulated, clinical trial material of an existing histone deacetylase inhibitor adapted for clinical testing in neurodevelopmental disorders following computational nomination and preclinical validation.

Home RNA collection kit for remote patient sampling

A swab-based kit designed to enable patients worldwide to self-collect RNA samples suitable for sequencing and molecular analysis.


Services

End-to-end patient-centered drug discovery service

Integrated service that collects patient RNA remotely, performs molecular analysis and in-silico prioritization, validates candidates in in vivo and rodent models, and supports clinical translation and trial execution in partnership with foundations and clinicians.

Patient RNA sequencing and dataset generation

Remote collection kit deployment and RNAseq generation to produce clinical-grade molecular datasets for rare and complex disorders.

Clinical translation and trial support

Clinical trial design, outcome measure validation, localized clinical tool translation, and assistance with patient recruitment and trial execution.

Expertise Areas

  • Patient-centered RNA-based discovery
  • Systems-biology network modeling
  • In-silico high-throughput screening
  • Preclinical in vivo screening (small whole-organism and rodent models)
  • Show More (6)

Key Technologies

  • RNA sequencing (RNAseq) from non-invasive swabs
  • Probabilistic network models / foundation models
  • AI-driven in-silico compound screening
  • Systems biology and molecular network inference
  • Show More (6)

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.